CClinicalTrials.gg
CompletedNCT04272567Updated Aug 4, 2020

Norepinephrine Prophylaxis for Postspinal Anesthesia Hypotension

An interventional study of Norepinephrine and Normal saline in Adverse Effect, sponsored by General Hospital of Ningxia Medical University. Completed at 1 site in China. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2020-08-04.

Sponsored by General Hospital of Ningxia Medical University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The purpose of this study is to investigate the suitable infusion dose of norepinephrine for prophylaxis against post-spinal anesthesia hypotension.

Read the detailed description

Post-spinal anesthesia hypotension is a frequent complication during spinal anesthesia for cesarean section. The incidence of post-spinal anesthesia hypotension is as high as 62.1-89.7% if prophylactic measures are not taken. Vasopressors has been highly recommended for routine prevention and/or treatment of post-spinal anesthesia hypotension. As a potential substitute drug for phenylephrine, norepinephrine has gradually been used in parturients undergoing cesarean section. There's some evidence that prophylactic infusion of norepinephrine could effectively reduce the incidence of post-spinal anesthesia hypotension in parturients undergoing cesarean section. But the ideal infusion dose of norepinephrine is still unknown. The purpose of this study is to investigate the suitable infusion dose of norepinephrine for prophylaxis against post-spinal anesthesia hypotension.

02

Conditions studied

  • Adverse Effect

Browse trials for

Keywords

  • Norepinephrine
  • Hypotension
  • Cesarean section
  • Dose-finding
03

In context

Hypotension

1,003 studies on the registry are indexed under Hypotension; 173 are open to participants now.

This study's enrollment of 99 is above the median of 80 across 675 interventional studies indexed under Hypotension.

Browse Hypotension studies →

Lead sponsor

General Hospital of Ningxia Medical University is the lead sponsor of 102 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • 18-40 years
  • Primipara or multipara
  • Singleton pregnancy ≥37 weeks
  • American Society of Anesthesiologists physical status classification I to II
  • Scheduled for elective cesarean section under spinal anesthesia

Exclusion criteria

Exclusion Criteria:

  • Body height \< 150 cm
  • Body weight > 100 kg or body mass index (BMI) ≥ 40 kg/m2
  • Eclampsia or chronic hypertension or baseline blood pressure ≥ 160mmHg
  • Hemoglobin \< 7g/dl
  • Fetal distress, or known fetal developmental anomaly
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
99 participants (actual)

Study arms

  • Sham comparator
    Control group

    Simultaneous with subarachnoid block, a bolus of 1ml normal saline was given followed by normal saline infusion

    Drug: Normal saline

  • Experimental
    0.025 μg/kg/min group

    Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.025 μg/kg/min).

    Drug: Norepinephrine

  • Experimental
    0.05 μg/kg/min group

    Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.05 μg/kg/min).

    Drug: Norepinephrine

  • Experimental
    0.075 μg/kg/min group

    Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.075 μg/kg/min).

    Drug: Norepinephrine

  • Experimental
    0.1 μg/kg/min group

    Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by a maintenance dose of norepinephrine (0.1 μg/kg/min).

    Drug: Norepinephrine

Interventions

  • DrugNorepinephrine

    Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by different infusion dose of norepinephrine.

    Also known as: Vasopressors

  • DrugNormal saline

    Simultaneous with subarachnoid block, a bolus of 1ml normal saline was given followed by normal saline infusion

    Also known as: NS

06

What researchers measure

Primary outcomes

  1. The incidence of post-spinal anesthesia hypotension

    Systolic blood pressure (SBP) \< 80% of the baseline

    Time frame: 1-15 minutes after spinal anesthesia.

Secondary outcomes

  1. Overall stability of systolic blood pressure control versus baseline

    Evaluated by performance error (PE).

    Time frame: 1-15 minutes after spinal anesthesia.

  2. Overall stability of heart rate control versus baseline

    Evaluated by performance error (PE).

    Time frame: 1-15 minutes after spinal anesthesia.

  3. The incidence of severe post-spinal anesthesia hypotension.

    Systolic blood pressure (SBP) \< 60% of the baseline.

    Time frame: 1-15 minutes after spinal anesthesia.

  4. The incidence of nausea and vomiting.

    Presence of nausea and vomiting in patients after spinal anesthesia

    Time frame: 1-15 minutes after spinal anesthesia.

  5. The incidence of bradycardia.

    Heart rate \< 55 beats/min.

    Time frame: 1-15 minutes after spinal anesthesia.

  6. The incidence of hypertension.

    Systolic blood pressure (SBP) \>120% of the baseline.

    Time frame: 1-15 minutes after spinal anesthesia.

  7. pH

    From umbilical arterial blood gases.

    Time frame: Immediately after delivery.

  8. Partial pressure of oxygen

    From umbilical arterial blood gases.

    Time frame: Immediately after delivery.

  9. Base excess

    From umbilical arterial blood gases.

    Time frame: Immediately after delivery.

  10. APGAR score

    A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration

    Time frame: 1min after delivery

  11. APGAR score

    A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration

    Time frame: 5min after delivery

07

Study locations

1 site
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750004, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04272567
Lead sponsor
General Hospital of Ningxia Medical University
Responsible party
Sponsor
First posted
Feb 17, 2020
Start date
Mar 28, 2020
Primary completion
Jun 30, 2020
Completion
Jun 30, 2020
Last update
Aug 4, 2020

Study contacts

Xinli Ni, Dr.
study chair · General Hospital of Ningxia Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion